Project Grant K99NS135117
- This $126,122 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at Oregon Health & Science University (OHSU) to elucidate the role of the protein CCNYL1 in oligodendrocyte differentiation and myelination. The project aims to define CCNYL1's function in oligodendrogenesis using zebrafish and mouse models, investigate related...
- This federal Project Grant award of $440,275.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to systematically discover upstream regulators of the OLIG2 transcription factor, which plays a central role in central nervous system myelination by oligodendrocytes. The award aims to identify enhancers and transcription factors that regulate OLIG2...
- This $576,142 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research conducted by Oregon Health & Science University (OHSU) to enhance understanding of oligodendrocyte (OL) development and myelination in the central nervous system. The key objectives of the 5-year project are to: Define the cellular mechanisms by which the...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is providing $426,938 to Virginia Commonwealth University to explore the role of a novel glutamate-driven signaling pathway initiated in maturing oligodendrocytes through the glutamate transporter GLT-1/EAAT2. This research aims to characterize the mechanisms downstream of...
- This Project Grant award of $429,514 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the regulation of myelin in the adult central nervous system. The primary objectives are to: Determine the activity dependence of myelin acquisition in the adult spinal cord. Investigate how tuberous sclerosis complex (TSC) signaling regulates myelin...
- This Project Grant award of $305,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of stem-like T cells in multiple sclerosis (MS) disease progression. The key objectives are to: Rigorously test the hypothesis that a continuing stemness and differentiation of CD4+ T stem cells results in functional and transcriptomic diversification under evolving...
- This $614,009 federal Project Grant award was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research into the molecular mechanisms of oligodendrocyte myelination and remyelination, which are critical processes for addressing demyelinating diseases of the central nervous system like multiple sclerosis. The awardee, Children's Hospital...
- This $198,928 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The grant will support research at the University of California, San Francisco to elucidate the cellular mechanisms underlying central nervous system injury and progression in multiple sclerosis. Key objectives include determining the role of astrocyte response,...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $235,500.00 to Rutgers, The State University to conduct research on the role of the choline transporter CTL1 in oligodendrocyte function and myelin formation. The goal is to elucidate the mechanism by which oligodendrocytes acquire choline, an essential nutrient for myelin lipid...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $506,083.00 to Artificial Axon Labs Inc. to develop a novel biomimetic 3D-printed drug discovery platform called "Artificial Axons" for screening remyelinating compounds to treat multiple sclerosis (MS) and other myelin diseases. The key products and services...
TRANSCRIPTIONAL REGULATION OF OLIGODENDROGLIAL DIFFERENTIATION - MULTIPLE SCLEROSIS (MS) IS A DEBILITATING DISORDER THAT AFFECTS 2.8 MILLION PEOPLE WORLDWIDE. MS IS CHARACTERIZED BY LOSS OF MYELIN, THE STRUCTURE SURROUNDING NERVES NECESSARY FOR EFFICIENT COMMUNICATION BETWEEN NEURONS AND CRITICAL TO NEURODEVELOPMENT, MAINTENANCE, AND PLASTICITY. THE SEVERE SYMPTOMS THAT ARISE AS MS PROGRESSES ARE EXACERBATED BY THE LOSS OF OLIGODENDROCYTES-THE MYELIN-PRODUCING CELLS-AND IMPAIRED DIFFERENTIATION OF THEIR PRECURSOR, OLIGODENDROCYTE PRECURSOR CELLS (OPCS). TO UNDERSTAND WHY REMYELINATION FAILS IN MS, WE FIRST NEED TO COMPREHEND THE MECHANISMS DRIVING THE PROLIFERATION AND DIFFERENTIATION OF MYELIN-FORMING PRECURSORS. OPCS ARE THE MOST ABUNDANTLY MITOTIC CELLS IN THE BRAIN AND MAINTAIN STRICT, HOMEOSTATIC BOUNDARIES, INDICATIVE OF A PRECISION IN CELL CYCLE CONTROL BUT ALSO AN ABILITY TO MAINTAIN ELABORATE TILING THROUGHOUT THE BRAIN DESPITE AN EVER-CHANGING MICROENVIRONMENT. OLIGODENDROGLIA DYNAMICS REQUIRE THE PRECISE TIMING OF TRANSCRIPTION FACTORS (TFS) EXPRESSION, THAT IS ESSENTIAL FOR EFFICIENTLY REMYELINATING LESIONS. THIS SUGGESTS A LARGE RANGE IN DYNAMIC PLASTICITY, A CHARACTERISTIC AFFORDED TO CELLS BY THE CIRCADIAN (~24 HOUR) CLOCK SYSTEM, A TRANSCRIPTIONAL-TRANSLATIONAL NEGATIVE FEEDBACK LOOP DRIVEN BY THE TRANSCRIPTION FACTORS BMAL1 AND CLOCK THAT REGULATES UP TO 50% OF THE MAMMALIAN TRANSCRIPTOME. WHILE MUCH IS KNOWN ABOUT THE VITAL ROLE OF CIRCADIAN RHYTHMS IN NEURONS, COMPARATIVELY LITTLE IS KNOWN ABOUT THEIR ROLE IN OLIGODENDROGLIAL CELLS. THERE IS STILL A SIGNIFICANT GAP IN OUR KNOWLEDGE OF THE GENETIC MECHANISMS THROUGH WHICH BMAL1 AND OTHER TFS CONTROL OPC DIFFERENTIATION DURING MYELINATION. MY CENTRAL HYPOTHESIS IS THAT THE DYNAMIC NATURE OF MYELIN-FORMING GLIA FOSTERED BY BMAL1 AND OTHER MASTER TRANSCRIPTIONAL REGULATORS CAN BE USED TO ENHANCE MYELINATION. THIS IS BASED ON MY DATA IN WHICH BMAL1 LOSS IN OPCS RESULTS IN TRANSCRIPTIONAL DYSREGULATION, ABERRANT OPC DYNAMICS AND MYELINATION. THESE DATA STRONGLY SUGGEST THE NECESSITY OF BMAL1 IN OPC DIFFERENTIATION AND MYELINATION. TO TEST THIS HYPOTHESIS, MY APPROACH WILL BE TO: 1) CHARACTERIZE THE ROLE OF BMAL1-THE ONLY SINGLE CLOCK FACTOR NECESSARY FOR CIRCADIAN RHYTHMICITY-IN OPC TRANSCRIPTIONAL REGULATION DURING NEURODEVELOPMENT THROUGH SINGLE-CELL RNASEQ AND CUT & TAG USING OUR ESTABLISHED CONDITIONAL CLOCK KNOCKOUT THAT LACKS BMAL1 IN OPCS; 2) EVALUATE THE RECOVERY OF THE DIFFERENTIATION POTENTIAL OF OPCS THAT LACK BMAL1 BY MODIFYING SIGNALING PATHWAYS THAT ACT DOWNSTREAM OF BMAL1; 3) STUDY THE TRANSCRIPTIONAL CONTROL OF REGULATORS OF HUMAN OPC DIFFERENTIATION THROUGH A CRISPR SCREEN IN HUMAN OPCS TO DISCOVER ENHANCERS. MY GOAL IS TO IDENTIFY NEW REGULATORY MECHANISMS OF OPC DIFFERENTIATION INTO MYELIN-FORMING CELLS, STARTING WITH THE ROLE OF BMAL1 IN OPC DYNAMICS, AND CONTINUING WITH GENOMIC ELEMENTS THAT CONTROL OPC DIFFERENTIATION. WITH THE K99/R00 AWARD, I WILL OBTAIN THE TRAINING TO PREPARE ME FOR A LIFELONG INDEPENDENT RESEARCH CAREER IN GENETIC REGULATION OF MYELIN-FORMING PRECURSORS. UNDERSTANDING THE MECHANISMS THAT REGULATE MYELIN-FORMING PRECURSORS WILL IMPART UNIQUE INSIGHTS INTO NORMAL AND ABERRANT MYELINATION AND HAVE A POSITIVE IMPACT ON DEVELOPING NEW THERAPEUTICS TO RESTRUCTURE MYELIN IN MS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $125.7k | 8/18/25 | ||
| Not listed | $0 | 9/9/24 | ||
| Not listed | $125.7k | 7/29/24 | ||
| Not listed | $125.7k | 7/29/24 |